Research ExplorerPublicationsBSc2118 is a novel proteasome inhibitor with activity agains...

BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma.

Standard

BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma. / Sterz, Jan; Jakob, Christian; Kuckelkorn, Ulrike; Heider, Ulrike; Mieth, Maren; Kleeberg, Lorenz; Kaiser, Martin; Kloetzel, Peter-M; Sezer, Orhan; von Metzler, Ivana.

In: EUR J HAEMATOL, Vol. 85, No. 2, 2, 2010, p. 99-107.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Sterz, J, Jakob, C, Kuckelkorn, U, Heider, U, Mieth, M, Kleeberg, L, Kaiser, M, Kloetzel, P-M, Sezer, O & von Metzler, I 2010, 'BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma.', EUR J HAEMATOL, vol. 85, no. 2, 2, pp. 99-107. <http://www.ncbi.nlm.nih.gov/pubmed/20374272?dopt=Citation>

APA

Sterz, J., Jakob, C., Kuckelkorn, U., Heider, U., Mieth, M., Kleeberg, L., Kaiser, M., Kloetzel, P-M., Sezer, O., & von Metzler, I. (2010). BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma. EUR J HAEMATOL, 85(2), 99-107. [2]. http://www.ncbi.nlm.nih.gov/pubmed/20374272?dopt=Citation

Vancouver

Sterz J, Jakob C, Kuckelkorn U, Heider U, Mieth M, Kleeberg L et al. BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma. EUR J HAEMATOL. 2010;85(2):99-107. 2.

Bibtex

@article{9cd5a626a524410caf7694dcf92c8a40,
title = "BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma.",
abstract = "The ubiquitin-proteasome system emerged as a new therapeutic target in cancer treatment. The purpose of this study was to elucidate the effects of the novel proteasome inhibitor BSc2118 on t(4;14) positive and negative multiple myeloma (MM) cells and normal peripheral blood mononuclear cells (PBMNC).",
keywords = "Humans, inhibitors, Cells, Cultured, Cell Line, Tumor, Oligopeptides pharmacology, Translocation, Genetic, Dose-Response Relationship, Drug, Antineoplastic Agents, Apoptosis drug effects, Bone Marrow Examination, Butanes pharmacology, Cell Cycle drug effects, Leukocytes, Mononuclear drug effects, Multiple Myeloma drug therapy, Proteasome Endopeptidase Complex antagonists, Humans, inhibitors, Cells, Cultured, Cell Line, Tumor, Oligopeptides pharmacology, Translocation, Genetic, Dose-Response Relationship, Drug, Antineoplastic Agents, Apoptosis drug effects, Bone Marrow Examination, Butanes pharmacology, Cell Cycle drug effects, Leukocytes, Mononuclear drug effects, Multiple Myeloma drug therapy, Proteasome Endopeptidase Complex antagonists",
author = "Jan Sterz and Christian Jakob and Ulrike Kuckelkorn and Ulrike Heider and Maren Mieth and Lorenz Kleeberg and Martin Kaiser and Peter-M Kloetzel and Orhan Sezer and {von Metzler}, Ivana",
year = "2010",
language = "Deutsch",
volume = "85",
pages = "99--107",
journal = "EUR J HAEMATOL",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma.

AU - Sterz, Jan

AU - Jakob, Christian

AU - Kuckelkorn, Ulrike

AU - Heider, Ulrike

AU - Mieth, Maren

AU - Kleeberg, Lorenz

AU - Kaiser, Martin

AU - Kloetzel, Peter-M

AU - Sezer, Orhan

AU - von Metzler, Ivana

PY - 2010

Y1 - 2010

N2 - The ubiquitin-proteasome system emerged as a new therapeutic target in cancer treatment. The purpose of this study was to elucidate the effects of the novel proteasome inhibitor BSc2118 on t(4;14) positive and negative multiple myeloma (MM) cells and normal peripheral blood mononuclear cells (PBMNC).

AB - The ubiquitin-proteasome system emerged as a new therapeutic target in cancer treatment. The purpose of this study was to elucidate the effects of the novel proteasome inhibitor BSc2118 on t(4;14) positive and negative multiple myeloma (MM) cells and normal peripheral blood mononuclear cells (PBMNC).

KW - Humans

KW - inhibitors

KW - Cells, Cultured

KW - Cell Line, Tumor

KW - Oligopeptides pharmacology

KW - Translocation, Genetic

KW - Dose-Response Relationship, Drug

KW - Antineoplastic Agents

KW - Apoptosis drug effects

KW - Bone Marrow Examination

KW - Butanes pharmacology

KW - Cell Cycle drug effects

KW - Leukocytes, Mononuclear drug effects

KW - Multiple Myeloma drug therapy

KW - Proteasome Endopeptidase Complex antagonists

KW - Humans

KW - inhibitors

KW - Cells, Cultured

KW - Cell Line, Tumor

KW - Oligopeptides pharmacology

KW - Translocation, Genetic

KW - Dose-Response Relationship, Drug

KW - Antineoplastic Agents

KW - Apoptosis drug effects

KW - Bone Marrow Examination

KW - Butanes pharmacology

KW - Cell Cycle drug effects

KW - Leukocytes, Mononuclear drug effects

KW - Multiple Myeloma drug therapy

KW - Proteasome Endopeptidase Complex antagonists

M3 - SCORING: Zeitschriftenaufsatz

VL - 85

SP - 99

EP - 107

JO - EUR J HAEMATOL

JF - EUR J HAEMATOL

SN - 0902-4441

IS - 2

M1 - 2

ER -